Luetkens Julian A, Kupczyk Patrick A, Doerner Jonas, Fimmers Rolf, Willinek Winfried A, Schild Hans H, Kukuk Guido M
Department of Radiology, University of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany.
Department of Medical Biometry, Informatics, and Epidemiology, University of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany.
Eur Radiol. 2015 Nov;25(11):3207-13. doi: 10.1007/s00330-015-3736-x. Epub 2015 Apr 23.
Our aim was to retrospectively evaluate the occurrence of respiratory motion artefacts in patients undergoing dynamic liver magnetic resonance (MR) either with gadoxetate disodium or gadobutrol.
Two hundred and thirty liver MR studies (115 with gadobutrol, 115 with gadoxetate disodium) were analysed. Respiratory motion artefacts on dynamic 3D T1-weighted MR images (pre-contrast, arterial, venous, and late-dynamic phase) were assessed using a five-point rating scale. Severe motion was defined as a score ≥ 4. Mean motion scores were compared with the Mann-Whitney-U-test. The chi-squared-test was used for dichotomous comparisons.
Mean motion scores for gadoxetate disodium and gadobutrol showed no relevant differences for each phase of the dynamic contrast series (pre-contrast: 1.85 ± 0.70 vs. 1.88 ± 0.57, arterial: 1.85 ± 0.81 vs. 1.87 ± 0.74, venous: 1.82 ± 0.67 vs. 1.74 ± 0.64, late-dynamic: 1.75 ± 0.62 vs. 1.79 ± 0.63; p = 0.469, 0.557, 0.382 and 0.843, respectively). Severe motion artefacts had a similar incidence using gadoxetate disodium and gadobutrol (11/460 [2.4%] vs. 7/460 [1.5%]; p = 0.341).
Gadoxetate disodium is associated with equivalent motion scores compared to gadobutrol in dynamic liver MRI. In addition, both contrast agents demonstrated a comparable and acceptable rate of severe respiratory motion artefacts.
• Gadobutrol and gadoxetate disodium showed comparable motion scores in dynamic phase imaging. • The incidence of severe motion artefacts was pronounced in arterial phase imaging. • Adverse respiratory side effects were not recorded in 115 examinations with gadoxetate disodium.
我们的目的是回顾性评估接受钆塞酸二钠或钆布醇动态肝脏磁共振成像（MR）检查的患者呼吸运动伪影的发生情况。
分析了230例肝脏MR研究（115例使用钆布醇，115例使用钆塞酸二钠）。使用五点评分量表评估动态三维T1加权MR图像（对比剂前、动脉期、静脉期和延迟动态期）上的呼吸运动伪影。严重运动定义为评分≥4分。使用Mann-Whitney-U检验比较平均运动评分。卡方检验用于二分法比较。
钆塞酸二钠和钆布醇在动态对比剂系列的各期平均运动评分无显著差异（对比剂前：1.85±0.70对1.88±0.57，动脉期：1.85±0.81对1.87±0.74，静脉期：1.82±0.67对1.74±0.64，延迟动态期：1.75±0.62对1.79±0.63；p分别为0.469、0.557、0.382和0.843）。使用钆塞酸二钠和钆布醇时严重运动伪影的发生率相似（11/460 [2.4%]对7/460 [1.5%]；p = 0.341）。
在动态肝脏MRI中，钆塞酸二钠与钆布醇的运动评分相当。此外，两种对比剂严重呼吸运动伪影的发生率相当且可接受。
•钆布醇和钆塞酸二钠在动态期成像中运动评分相当。•严重运动伪影的发生率在动脉期成像中较为明显。•在115例钆塞酸二钠检查中未记录到不良呼吸副作用。
